Hvivo PLC (HVO) Given Add Rating at Numis Securities Ltd

Hvivo PLC (LON:HVO)‘s stock had its “add” rating restated by analysts at Numis Securities Ltd in a research note issued to investors on Thursday. They currently have a GBX 210 ($2.74) target price on the stock. Numis Securities Ltd’s target price suggests a potential upside of 18.31% from the company’s previous close.

Hvivo PLC (LON:HVO) opened at 174.5876 on Thursday. The firm has a 50-day moving average of GBX 180.66 and a 200 day moving average of GBX 186.26. The stock’s market cap is GBX 136.27 million. Hvivo PLC has a 12 month low of GBX 167.00 and a 12 month high of GBX 306.50.

In other news, insider Ellertson,Jaime acquired 7,801 shares of the business’s stock in a transaction dated Wednesday, August 3rd. The stock was acquired at an average price of GBX 187 ($2.44) per share, with a total value of £14,587.87 ($19,041.73).

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/hvivo-plc-hvo-given-add-rating-at-numis-securities-ltd.html

Hvivo PLC Company Profile

Hvivo PLC is the United Kingdom-based holding company. The Company is a virology healthcare business that provides clinical services, focused on the Human Challenge Model (HCM) primarily to pharmaceutical companies and biotechnology organizations. The Company has grown and developed the HCM for evidencing the efficiency of antiviral and viral therapeutics in RSV, flu and cold.

Receive News & Ratings for Hvivo PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

 

Hvivo PLC (HVO) Given Add Rating at Numis Securities Ltd

Hvivo PLC (LON:HVO)‘s stock had its “add” rating restated by analysts at Numis Securities Ltd in a research note issued to investors on Thursday. They currently have a GBX 210 ($2.74) target price on the stock. Numis Securities Ltd’s target price suggests a potential upside of 18.31% from the company’s previous close.

Hvivo PLC (LON:HVO) opened at 174.5876 on Thursday. The firm has a 50-day moving average of GBX 180.66 and a 200 day moving average of GBX 186.26. The stock’s market cap is GBX 136.27 million. Hvivo PLC has a 12 month low of GBX 167.00 and a 12 month high of GBX 306.50.

In other news, insider Ellertson,Jaime acquired 7,801 shares of the business’s stock in a transaction dated Wednesday, August 3rd. The stock was acquired at an average price of GBX 187 ($2.44) per share, with a total value of £14,587.87 ($19,041.73).

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/hvivo-plc-hvo-given-add-rating-at-numis-securities-ltd.html

Hvivo PLC Company Profile

Hvivo PLC is the United Kingdom-based holding company. The Company is a virology healthcare business that provides clinical services, focused on the Human Challenge Model (HCM) primarily to pharmaceutical companies and biotechnology organizations. The Company has grown and developed the HCM for evidencing the efficiency of antiviral and viral therapeutics in RSV, flu and cold.

Receive News & Ratings for Hvivo PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

 
Content on this website is not meant to be a recommendation or an offer to buy or sell any security. Click here to read our full disclaimer.